My top UK shares to buy and hold in the healthcare sector

Many medical and healthcare stocks are yet to fully recover from the pandemic. Here are my top UK shares to buy in the sector.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A pastel colored growing graph with rising rocket.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I believe medical and healthcare stocks represent some of the top UK shares to buy and hold right now. Stocks in the industry suffered greatly during the pandemic as resources were reallocated towards treating Covid-19. Many stocks in the sector are yet to recover and share prices still sit below pre-pandemic levels. This is the case despite pent-up demand for elective and private medical procedures.

In England alone, there are now more than six million people waiting on elective procedures. What’s more, there is considerable political will to reduce the waiting list and I think medical device companies and private healthcare providers stand to profit.

The two stocks I want to look at today are medical device giant Smith & Nephew (LSE:SN) and private hospital firm Spire Healthcare (LSE:SPI).

Smith & Nephew

I think Smith & Nephew is a good buy for my portfolio. But while it has a passive-income offering, I’m more interested in its upside potential.

As I write, the medical device giant is trading at around 1,215p per share, considerably discounted from a year-high of 1,592p in July 2021. The share price threatened to push above 2,000p for the first time prior to the Covid-19 pandemic.

The London-headquartered firm returned a profit in 2020 and 2021 despite the tough operating environment. The $586m pre-tax profit in 2021 was some distance behind the $743m recorded in 2019, but it’s worth remembering that the start of 2021 saw record Covid-induced hospitalisations.

There’s certainly ongoing risks for this sector as Covid-19 continues to linger. Of course, it is highly likely new variants will emerge, but we can only hope they’re less virulent and contagious.

Despite this, I feel confident that 2022 will be more profitable for Smith & Nephew. I see it benefitting from sizeable waiting lists and pent-up demand for elective procedures.

Spire Healthcare Group

The Spire Healthcare Group doesn’t fit in perfectly with the category of ailing medical and healthcare providers. Its share price is actually above 2018 and 2019 levels when the company registered growth issues.

Last summer, the share price jumped around 25% in a day following a proposed acquisition by Australia’s Ramsay Health Care. The deal fell through but the share price has remained around the 240p mark ever since.

However, the Spire share price – around 244p as I write – is hugely discounted compared to the near-400p seen in 2016. Personally, I think the share price will return to these levels on the back of huge demand for medical procedures.

Research by the Institute for Public Policy Research suggests that the pandemic prompted more people to purchase private health insurance or pay for treatment as the NHS struggled to keep up with demand. And with more than six million people waiting for NHS treatments, I’m confident that the Spire Healthcare Group will do a roaring trade this year and the next.

I have recently bought shares in both these companies and may buy more soon.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James Fox owns shares in Smith & Nephew and Spire Healthcare. The Motley Fool UK has recommended Smith & Nephew. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »